{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T21:04:01Z","timestamp":1757624641415,"version":"3.44.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"King Abdullah International Medical Research Centre","award":["NRJ22J\/244\/07"],"award-info":[{"award-number":["NRJ22J\/244\/07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-025-01696-1","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T10:14:35Z","timestamp":1756116875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical value of the EpCAM biomarker and its association with immune cell infiltration in bladder cancer"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-7118","authenticated-orcid":false,"given":"Taoufik","family":"Nedjadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hifzur R.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"Aouabdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Samkari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaudah","family":"Al-Maghrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"1696_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1696_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41585-023-00804-4","volume":"20","author":"E Laukhtina","year":"2023","unstructured":"Laukhtina E, Shariat SF. Smoking, ethnicity and bladder cancer - implications for public health and clinical practice. Nat Rev Urol. 2023;20(11):643\u20134.","journal-title":"Nat Rev Urol"},{"key":"1696_CR3","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat Reviews Disease Primers. 2017;3:17022.","journal-title":"Nat Reviews Disease Primers"},{"issue":"19","key":"1696_CR4","first-page":"1980","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: Rev Jama. 2020;324(19):1980\u201391.","journal-title":"Bladder Cancer: Rev Jama"},{"issue":"2","key":"1696_CR5","doi-asserted-by":"publisher","first-page":"188436","DOI":"10.1016\/j.bbcan.2020.188436","volume":"1874","author":"F Fagotto","year":"2020","unstructured":"Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration, and potential impact on invasion: A critical review. Biochim Et Biophys Acta Reviews Cancer. 2020;1874(2):188436.","journal-title":"Biochim Et Biophys Acta Reviews Cancer"},{"issue":"5","key":"1696_CR6","first-page":"192","volume":"68","author":"R Wen","year":"2022","unstructured":"Wen R, Lin H, Li X, Lai X, Yang F. The regulatory mechanism of EpCAM N-Glycosylation-Mediated MAPK and PI3K\/Akt pathways on Epithelial-Mesenchymal transition in breast cancer cells. Cellular and molecular biology. France). 2022;68(5):192\u2013201. (Noisy-le-Grand.","journal-title":"France)"},{"key":"1696_CR7","doi-asserted-by":"crossref","unstructured":"Fagotto F. EpCAM as modulator of tissue plasticity. Cells. 2020;9(9).","DOI":"10.3390\/cells9092128"},{"key":"1696_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijsu.2018.06.025","volume":"56","author":"L Zhou","year":"2018","unstructured":"Zhou L, Zhu Y. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis. Int J Surg (London England). 2018;56:274\u201380.","journal-title":"Int J Surg (London England)"},{"key":"1696_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2022.01.120","volume":"600","author":"SD Shinde","year":"2022","unstructured":"Shinde SD, Rao KB, Behera SK, Arya N, Sahu B. Epithelial cell adhesion molecule (EpCAM) binding short peptides derived from antibody MOC-31; De-novo design, synthesis and their in-vitro evaluation. Biochem Biophys Res Commun. 2022;600:1\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1696_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/modpathol.3800534","volume":"19","author":"H Yaziji","year":"2006","unstructured":"Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathology: Official J United States Can Acad Pathol Inc. 2006;19(4):514\u201323.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"issue":"3","key":"1696_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/modpathol.3800544","volume":"19","author":"NG Ord\u00f3\u00f1ez","year":"2006","unstructured":"Ord\u00f3\u00f1ez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathology: Official J United States Can Acad Pathol Inc. 2006;19(3):417\u201328.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"issue":"Suppl 1","key":"1696_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","volume":"9","author":"DB Chapel","year":"2020","unstructured":"Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Translational Lung Cancer Res. 2020;9(Suppl 1):S3\u201327.","journal-title":"Translational Lung Cancer Res"},{"key":"1696_CR13","doi-asserted-by":"crossref","unstructured":"Eslami SZ, Cort\u00e9s-Hern\u00e1ndez LE, Alix-Panabi\u00e8res C. Epithelial cell adhesion molecule: an anchor to isolate clinically relevant Circulating tumor cells. Cells. 2020;9(8).","DOI":"10.3390\/cells9081836"},{"issue":"1","key":"1696_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s41598-018-19391-1","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Peng M, Li N, Song Q, Yao Y, Xu B, et al. Combined use of EpCAM and FR\u03b1 enables the high-efficiency capture of Circulating tumor cells in non-small cell lung cancer. Sci Rep. 2018;8(1):1188.","journal-title":"Sci Rep"},{"issue":"9","key":"1696_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2174\/1568009618666180102102311","volume":"18","author":"S Eyvazi","year":"2018","unstructured":"Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M. Antibody based EpCAM targeted therapy of cancer, review and update. Curr Cancer Drug Targets. 2018;18(9):857\u201368.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"1696_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1186\/s12885-018-5010-5","volume":"18","author":"J Ni","year":"2018","unstructured":"Ni J, Cozzi P, Beretov J, Duan W, Bucci J, Graham P, et al. Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy\/radiotherapy response in vivo. BMC Cancer. 2018;18(1):1092.","journal-title":"BMC Cancer"},{"issue":"6","key":"1696_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1517\/14712598.2010.482098","volume":"10","author":"JE Kurtz","year":"2010","unstructured":"Kurtz JE, Dufour P. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010;10(6):951\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1696_CR18","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.4317\/medoral.25145","volume":"27","author":"N Derderian","year":"2022","unstructured":"Derderian N, Pereira-Prado V, Hernandez M, Isiordia-Espinoza M, Arocena M, Gonzalez-Gonzalez R, et al. Ep-CAM (MOC-31) expression in tooth germ and ameloblastoma. Med Oral Patol Oral Cir Bucal. 2022;27(5):e403\u20139.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"9","key":"1696_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/PAI.0000000000000826","volume":"28","author":"O Lopez-Nunez","year":"2020","unstructured":"Lopez-Nunez O, Ranganathan S. Immunohistochemical expression analysis of EpCAM in hepatoblastomas. Appl Immunohistochem Mol Morphol. 2020;28(9):711\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8","key":"1696_CR20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/PAI.0000000000000664","volume":"27","author":"P Gill","year":"2019","unstructured":"Gill P, Naugler C, Abi Daoud MS. Utility of Ber-EP4 and MOC-31 in basaloid skin tumor detection. Appl Immunohistochem Mol Morphol. 2019;27(8):584\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1696_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12885-016-2703-5","volume":"16","author":"T Nedjadi","year":"2016","unstructured":"Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016;16:653.","journal-title":"BMC Cancer"},{"issue":"3","key":"1696_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s12253-018-0477-6","volume":"25","author":"T Nedjadi","year":"2019","unstructured":"Nedjadi T, Salem N, Khayyat D, Al-Sayyad A, Al-Ammari A, Al-Maghrabi J. Sonic Hedgehog expression is associated with lymph node invasion in urothelial bladder cancer. Pathol Oncol Res. 2019;25(3):1067\u201373.","journal-title":"Pathol Oncol Res"},{"issue":"D1","key":"1696_CR23","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313.","journal-title":"Nucleic Acids Res"},{"key":"1696_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-59745-545-9_4","volume":"576","author":"AM Dancau","year":"2010","unstructured":"Dancau AM, Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Biol. 2010;576:49\u201360.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"1696_CR25","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1038\/bjc.2017.417","volume":"118","author":"TA Barnes","year":"2018","unstructured":"Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2018;118(2):e5.","journal-title":"Br J Cancer"},{"issue":"5","key":"1696_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17(5):259\u201370.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"1696_CR27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61(5):1039\u201347.","journal-title":"Eur Urol"},{"key":"1696_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1475-2867-10-44","volume":"10","author":"M M\u00fcnz","year":"2010","unstructured":"M\u00fcnz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S, et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int. 2010;10:44.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"1696_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.15698\/cst2019.06.188","volume":"3","author":"L Keller","year":"2019","unstructured":"Keller L, Werner S, Pantel K. Biology and clinical relevance of EpCAM. Cell Stress. 2019;3(6):165\u201380.","journal-title":"Cell Stress"},{"issue":"2","key":"1696_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ncb1824","volume":"11","author":"D Maetzel","year":"2009","unstructured":"Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162\u201371.","journal-title":"Nat Cell Biol"},{"key":"1696_CR31","doi-asserted-by":"crossref","unstructured":"Brown TC, Sankpal NV, Gillanders WE. Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition. Biomolecules. 2021;11(7).","DOI":"10.3390\/biom11070956"},{"issue":"1","key":"1696_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"PT Went","year":"2004","unstructured":"Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122\u20138.","journal-title":"Hum Pathol"},{"issue":"1","key":"1696_CR33","doi-asserted-by":"publisher","first-page":"e23505","DOI":"10.1016\/j.heliyon.2023.e23505","volume":"10","author":"M Chen","year":"2024","unstructured":"Chen M, Gao Y, Cao H, Wang Z, Zhang S. Comprehensive analysis reveals dual biological function roles of EpCAM in kidney renal clear cell carcinoma. Heliyon. 2024;10(1):e23505.","journal-title":"Heliyon"},{"issue":"8","key":"1696_CR34","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/j.bbamem.2013.04.018","volume":"1828","author":"U Schnell","year":"2013","unstructured":"Schnell U, Cirulli V, Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta. 2013;1828(8):1989\u20132001.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1696_CR35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1940-6207.CAPR-09-0189","volume":"3","author":"R Stone","year":"2010","unstructured":"Stone R 2nd, Sabichi AL, Gill J, Lee IL, Adegboyega P, Dai MS, et al. Identification of genes correlated with early-stage bladder cancer progression. Cancer Prev Res (Phila). 2010;3(6):776\u201386.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"1696_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, et al. Comprehensive transcriptional analysis of Early-Stage urothelial carcinoma. Cancer Cell. 2016;30(1):27\u201342.","journal-title":"Cancer Cell"},{"key":"1696_CR37","doi-asserted-by":"crossref","unstructured":"Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM. Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. Nat Rev Urol. 2024.","DOI":"10.1038\/s41585-024-00914-7"},{"issue":"10","key":"1696_CR38","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/labinvest.3780347","volume":"81","author":"A Hoos","year":"2001","unstructured":"Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 2001;81(10):1331\u20138.","journal-title":"Lab Invest"},{"issue":"12","key":"1696_CR39","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/labinvest.3780204","volume":"80","author":"RL Camp","year":"2000","unstructured":"Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80(12):1943\u20139.","journal-title":"Lab Invest"},{"issue":"6","key":"1696_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/(SICI)1097-0142(19991225)87:6<390::AID-CNCR10>3.0.CO;2-4","volume":"87","author":"RL Morgan","year":"1999","unstructured":"Morgan RL, De Young BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer. 1999;87(6):390\u20134.","journal-title":"Cancer"},{"issue":"6","key":"1696_CR41","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1007\/s13277-014-1795-2","volume":"35","author":"D Li","year":"2014","unstructured":"Li D, Wang B, Hu Q, Shen Y, Xu D, Wang T, et al. Diagnostic accuracy of MOC-31 for malignant effusions: a meta-analysis. Tumour Biology: J Int Soc Oncodevelopmental Biology Med. 2014;35(6):6003\u20139.","journal-title":"Tumour Biology: J Int Soc Oncodevelopmental Biology Med"},{"issue":"11","key":"1696_CR42","first-page":"1066","volume":"99","author":"S Ben Rejeb","year":"2021","unstructured":"Ben Rejeb S, Beltaifa D, Ghozzi A, Bellil K, Turki S. EpCAM (MOC-31) - immunohistochemical expression in papillary thyroid carcinoma and Non invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Tunis Med. 2021;99(11):1066\u201371.","journal-title":"Tunis Med"},{"issue":"3","key":"1696_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/PAI.0b013e31818c0f42","volume":"17","author":"RK Pai","year":"2009","unstructured":"Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. Appl Immunohistochem Mol Morphol. 2009;17(3):202\u20136.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"1696_CR44","first-page":"1471","volume":"18","author":"JS Lewis","year":"2005","unstructured":"Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Modern pathology: an official journal of the united States and Canadian academy of pathology. Inc. 2005;18(11):1471\u201381.","journal-title":"Inc"},{"issue":"18","key":"1696_CR45","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1158\/1078-0432.CCR-08-0669","volume":"14","author":"M Schmidt","year":"2008","unstructured":"Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Research: Official J Am Association Cancer Res. 2008;14(18):5849\u201355.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"12","key":"1696_CR46","doi-asserted-by":"publisher","first-page":"13372","DOI":"10.18632\/oncotarget.5618","volume":"7","author":"JH Kim","year":"2016","unstructured":"Kim JH, Bae JM, Song YS, Cho NY, Lee HS, Kang GH. Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma. Oncotarget. 2016;7(12):13372\u201387.","journal-title":"Oncotarget"},{"issue":"3","key":"1696_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/2357-0121.199354","volume":"1","author":"MA Ahmed","year":"2016","unstructured":"Ahmed MA, Badary FA, Yassin EH, Mohammed SA, El-Attar MM. Differential expression of MOC-31, hep par 1, and N-cadherin in primary carcinoma and metastatic adenocarcinoma in the liver. J Curr Med Res Pract. 2016;1(3):54\u201360.","journal-title":"J Curr Med Res Pract"},{"issue":"12","key":"1696_CR48","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/01.MP.0000037312.69565.24","volume":"15","author":"C Morrison","year":"2002","unstructured":"Morrison C, Marsh W Jr., Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathology: Official J United States Can Acad Pathol Inc. 2002;15(12):1279\u201387.","journal-title":"Mod Pathology: Official J United States Can Acad Pathol Inc"},{"issue":"2","key":"1696_CR49","first-page":"429","volume":"60","author":"EC Andriescu","year":"2019","unstructured":"Andriescu EC, Giu\u015fc\u0103 SE, Ciobanu Apostol DG, Lozneanu L, C\u0103runtu ID. EpCAM (MOC-31) - immunohistochemical profile and clinico-pathological correlations in different histological variants of papillary thyroid carcinoma. Romanian J Morphology Embryol = Revue Roumaine De Morphologie Et Embryologie. 2019;60(2):429\u201336.","journal-title":"Romanian J Morphology Embryol = Revue Roumaine De Morphologie Et Embryologie"},{"issue":"3","key":"1696_CR50","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/jcp.2007.049460","volume":"61","author":"A Brunner","year":"2008","unstructured":"Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol. 2008;61(3):307\u201310.","journal-title":"J Clin Pathol"},{"issue":"12","key":"1696_CR51","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1097\/PAS.0b013e318265288c","volume":"36","author":"S Dhayat","year":"2012","unstructured":"Dhayat S, Sorescu S, Vallb\u00f6hmer D, Kraus S, Baldus SE, Rehders A, et al. Prognostic significance of EpCAM-positive disseminated tumor cells in rectal cancer patients with stage I disease. Am J Surg Pathol. 2012;36(12):1809\u201316.","journal-title":"Am J Surg Pathol"},{"key":"1696_CR52","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2407-12-523","volume":"12","author":"T Kunavisarut","year":"2012","unstructured":"Kunavisarut T, Kak I, Macmillan C, Ralhan R, Walfish PG. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma. BMC Cancer. 2012;12:523.","journal-title":"BMC Cancer"},{"key":"1696_CR53","doi-asserted-by":"crossref","unstructured":"Xiao D, Xiong M, Wang X, Lyu M, Sun H, Cui Y et al. Regulation of the function and expression of EpCAM. Biomedicines. 2024;12(5).","DOI":"10.3390\/biomedicines12051129"},{"issue":"47","key":"1696_CR54","doi-asserted-by":"publisher","first-page":"39449","DOI":"10.1074\/jbc.M112.386235","volume":"287","author":"CW Lin","year":"2012","unstructured":"Lin CW, Liao MY, Lin WW, Wang YP, Lu TY, Wu HC. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem. 2012;287(47):39449\u201359.","journal-title":"J Biol Chem"},{"key":"1696_CR55","doi-asserted-by":"crossref","unstructured":"Xu T, Vorobyeva A, Schulga A, Konovalova E, Vorontsova O, Ding H et al. Imaging-Guided therapy simultaneously targeting HER2 and EpCAM with trastuzumab and EpCAM-Directed toxin provides additive effect in ovarian cancer model. Cancers (Basel). 2021;13(16).","DOI":"10.3390\/cancers13163939"},{"key":"1696_CR56","doi-asserted-by":"crossref","unstructured":"Park DJ, Sung PS, Kim JH, Lee GW, Jang JW, Jung ES et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8(1).","DOI":"10.1136\/jitc-2019-000301"},{"issue":"22","key":"1696_CR57","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1158\/0008-5472.CAN-20-1264","volume":"80","author":"HN Chen","year":"2020","unstructured":"Chen HN, Liang KH, Lai JK, Lan CH, Liao MY, Hung SH, et al. EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway. Cancer Res. 2020;80(22):5035\u201350.","journal-title":"Cancer Res"},{"key":"1696_CR58","doi-asserted-by":"crossref","unstructured":"Zhang Y, Xie X, Yeganeh PN, Lee DJ, Valle-Garcia D, Meza-Sosa KF et al. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. Proc Natl Acad Sci U S A. 2021;118(9).","DOI":"10.1073\/pnas.2022830118"},{"issue":"5","key":"1696_CR59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jasc.2019.04.003","volume":"8","author":"RC Weimholt","year":"2019","unstructured":"Weimholt RC, Sharifai N, Abro B, Vij K, Bernadt C. Reactivity with the EpCAM-specific antibodies MOC-31 and Ber-Ep4 in plasma cell neoplasms: a potential diagnostic pitfall in cytology samples. J Am Soc Cytopathol. 2019;8(5):265\u20139.","journal-title":"J Am Soc Cytopathol"},{"issue":"9","key":"1696_CR60","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1007\/s00262-021-02930-7","volume":"70","author":"P Ruf","year":"2021","unstructured":"Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunol Immunotherapy: CII. 2021;70(9):2727\u201335.","journal-title":"Cancer Immunol Immunotherapy: CII"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01696-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01696-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01696-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T14:01:37Z","timestamp":1757426497000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01696-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01696-1","relation":{},"ISSN":["1746-1596"],"issn-type":[{"type":"electronic","value":"1746-1596"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the principles of the Declaration of Helsinki. The Ethics Committee of King Abdulaziz University Hospital, Jeddah, Saudi Arabia (Ref #77\u2009\u2212\u200921), approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"Written informed consent was obtained from all participants in this study, and both clinical and follow-up data were retrieved according to the permission and guidelines of the Ethical Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}